Hyperfine, Inc.

As of September 11, 2025, Hyperfine, Inc. is in a mildly bullish trend, supported by a bullish MACD and daily moving average, despite bearish momentum indicated by the weekly RSI, while outperforming the S&P 500 with a year-to-date return of 57.95%.

As of May 11, 2022, Hyperfine, Inc. is considered a risky investment and overvalued due to negative performance metrics, with a Price to Book Value of 1.44 and a concerning EV to Sales ratio of 2.45, while its EV to EBITDA ratio of -0.68 significantly lags behind peers, contributing to a year-to-date decline of 21.17% compared to the S&P 500's 2.44% gain.

As of June 2, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some positive signals from weekly and monthly indicators.

Hyperfine, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $9 million as of March 2025, with a market cap of $54.51 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -96.28%.

As of Jun 18, Hyperfine, Inc. has a market capitalization of 54.51 million and reported net sales of 11.73 million with a net profit of -40.30 million over the last four quarters. Shareholder's funds are 49.04 million, and total assets are 58.90 million.